All In Biotech

Drug Trial Radar · NCT05704361

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

A Multiple-center, Non-randomized, Open-label, Adaptive, Single-ascending Dose (Part 1 and Part 2) and Multiple-ascending Dose (Part 3), and Long-term Safety (Part 4), Parallel, Phase IB Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 Following Intravenous (Parts 1 and 4) and Subcutaneous (Parts 2, 3 and 4) Administration in Participants With Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

119

Planned (sponsor's estimate)

Start

Aug 11, 2021

Primary completion

Jul 8, 2027

Study completion Jul 8, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3), and multiple-ascending SC doses following a single IV dose (Part 4) of RO7121932 in participants with multiple sclerosis (MS). Only Parts 1 and 2 of the study will be conducted in the United States, whereas Parts 1, 2, 3, and 4 will be conducted in all other participating countries outside the United States.

Conditions

  • Multiple Sclerosis

Interventions

  • RO7121932 IVDrug

    Participants will receive RO7121932, as an IV infusion, per the schedule specified in the treatment arms.

  • RO7121932 SCDrug

    Participants will receive RO7121932, as SC injection, per the schedule specified in the treatment arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1, 2, 3, and 4: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) With Severity of AEs Measured According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5 (NCI CTCAE V5)Time frame: Day 1 to Day 169 for Part 1 and Part 2; Day 1 to Day 197 for Part 3; Day 1 to Day 253 for Part 4
  2. Parts 1, 2, 3, and 4: Change From Baseline in Suicide Risk as Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Day 1 to Day 169 for Part 1 and Part 2; Day 1 to Day 197 for Part 3; Day 1 to Day 253 for Part 4
  3. Parts 2 and 3: Percentage of Participants With Local Pain at the Site of Injection Assessed Using the Visual Analog Scale (VAS)Time frame: Day 1, 2, 5, 8 for Part 2; Day 1, 2, 5, 8, 15, 22, 29, 36 for Part 3
  4. Parts 2 and 3: Percentage of Participants With Local Injection-site Reaction Using Local Injection-site Symptom Assessment (LISSA)Time frame: Day 1,2, 5, 8 for Part 2; Day 1, 2, 5, 8, 15, 22, 29, 36 for Part 3
  5. Part 4: Percentage of Participants With Local Injection-site ReactionsTime frame: Day 1 to Day 253

Locations

26 sites in 12 countries. Site status is shown where the registry gives one.

  • Stanford University Medical Center

    Stanford, California

  • Yale University Multiple Sclerosis Center

    New Haven, Connecticut

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • Montreal Neurological Institute and Hospital

    Montreal, Quebec, Canada

  • Universitätsklinikum "Carl Gustav Carus"

    Dresden, Germany

  • Universitätsmedizin Göttingen Georg-August-Universität

    Göttingen, Germany

  • Klinikum rechts der Isar der TU Muenchen

    München, Germany

  • Universitätsklinikum Münster Klinik u. Poliklinik f. Neurologie

    Münster, Germany

  • Universitätsklinikum Tübingen, Zentrum für Neurologie

    Tübingen, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Hadassah University Hospital - Ein Kerem

    Jerusalem, Israel

  • IRCCS Ospedale San Raffaele

    Milan, Lombardy, Italy

  • Fond. Istituto Neurologico C.Besta

    Milan, Lombardy, Italy

  • ARENSIA Exploratory Medicine Phase I, PMSI Republican Clinical Hospital

    Chisinau, Moldova

  • Regionalny Szpital Specjalistyczny im. W. Bieganskiego

    Grudzi?dz, Poland

  • MedPolonia

    Poznan, Poland

  • Osrodek Badan Klinicznych Euromedis

    Szczecin, Poland

  • SPSK nr 1

    Zabrze, Poland

  • Hospital de Braga

    Braga, Portugal

  • Hospital Santo Antonio dos Capuchos

    Lisbon, Portugal

  • Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião

    Santa Maria da Feira, Portugal

  • ARENSIA Exploratory Medicine SRL - Bucharest (Monza Medical Center)

    Bucharest, Romania

  • ARENSIA Exploratory Medicine, County Emergency Hospital

    Cluj-Napoca, Romania

  • University Clinical Center of Serbia

    Belgrade, Serbia

  • Hospital Universitari Vall dHebron (CEMCAT)

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.